Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Neuro-Oncology
•
Medical Oncology
•
Neurology
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
Related Questions
How will you select patients with brain metastases for TTFields?
How would you approach a patient with recurrent grade 3 oligodendroglioma (MGMT-methylated, IDH mutant, 1p/19q co-deleted) 1 year after gross total resection and adjuvant chemotherapy and radiation?
What would be your radiotherapy plan for a patient with recurrent GBM (WHO grade 4, IDH wild-type) s/p 2 prior resections with no prior radiation?
Are you offering Lutathera for multiple recurrent meningiomas?
What are your top takeaways in Neuro Oncology from ASCO 2025?
How would you advise a younger patient with residual/recurrent optic nerve meningioma, proceeding with radiotherapy, about the risks of malignant transformation or induction of other brain malignancies because of radiation?
Is there a role for bevacizimab (IV or IA) for steroid refractory radionecrosis for AVM?
Do you utilize tumor treating fields in patients with anaplastic pleomorphic xanthoastrocytoma (PXA) III?
Would patients receiving targeted therapies be eligible for TTFields for brain metastases?
In what circumstances would you consider use of IDH inhibitors in high-grade astrocytomas?
